2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors
Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors. Cancer 2015, 121: 1817-1826. PMID: 25649370, DOI: 10.1002/cncr.29254.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityIntravenous nab-paclitaxelPhase 1b studyAdvanced solid tumorsNab-paclitaxelFDG activityDay 1Solid tumorsNanoparticle albumin-bound paclitaxelMammalian targetWeekly oral doseAcceptable safety profileRapamycin inhibitor sirolimusAlbumin-bound paclitaxelClinical trial endpointsExploratory gene expression analysisPositron emission tomographyStable diseaseTaxane therapyPartial responseWeekly doseComplete responseOral sirolimusPharmacodynamic assessmentOral dose
2014
Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence
Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK. Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence. Cancer Prevention Research 2014, 7: 896-905. PMID: 24950779, PMCID: PMC4154987, DOI: 10.1158/1940-6207.capr-13-0408.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrogen AntagonistsAnimalsAntineoplastic Agents, HormonalArea Under CurveBiomarkers, TumorEnzyme-Linked Immunosorbent AssayFallopian Tube NeoplasmsFallopian TubesFemaleFlutamideGenetic Predisposition to DiseaseHumansImmunohistochemistryMacrophage Colony-Stimulating FactorMaleMiceMice, NudeMiddle AgedOvarian NeoplasmsOvariectomyOvaryReceptor, ErbB-4Risk FactorsROC CurveSalpingectomyConceptsOvarian endosalpingiosisOvarian stromaFlutamide treatmentOvarian cancerHigh riskBRCA carrier statusOvarian cancer initiationPhase II studyRole of androgensPelvic serous cancerEffect of flutamideOvarian cancer developmentCSF-1High predictive valueLogistic regression modelsAndrogen ablationII studySerous cancerTumor burdenClinical evidenceBRCA mutationsFallopian tubeCSF-1RMale miceAndrogen action
2011
A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study
El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study. Gynecologic Oncology 2011, 124: 471-473. PMID: 22014628, DOI: 10.1016/j.ygyno.2011.09.029.Peer-Reviewed Original ResearchConceptsWithdrawal of carePercent of respondentsGynecologic oncologistsLife discussionsAdvanced-stage cancerProgression of diseaseYears of ageFirst recurrenceMajor surgeryPatient ageHalf of respondentsStage cancerMedical statusResponse rateTumor sitePatientsOncologistsPilot studyPilot surveyHealth insuranceInitial responseSurvey MonkeyAgeSocial supportCare